Association between systemic immune-inflammatory markers and the risk of moyamoya disease: a case-control study

References

• Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009;360(12):1–9. doi:10.1056/NEJMra0804622.
   PubMed Web of Science ®Google Scholar
• Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet. 2011;56(1):34–40. doi:10.1038/jhg.2010.132.
   PubMed Web of Science ®Google Scholar
• Mikami T, Suzuki H, Komatsu K, et al. Influence of inflammatory disease on the pathophysiology of moyamoya disease and quasi-moyamoya disease. Neurol Med Chir. 2019;59(10):361–370. doi:10.2176/nmc.ra.2019-0059.
   PubMed Web of Science ®Google Scholar
• Ferro D, Matias M, Neto J, et al. Neutrophil-to-lymphocyte ratio predicts cerebral edema and clinical worsening early after reperfusion therapy in stroke. Stroke. 2021;52(3):859–867.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhou S, Liu Y, et al. Prognostic value of systemic inflammatory markers in ovarian cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer. 2018;18(1):443.
   PubMedGoogle Scholar
• Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–38.
   PubMed Web of Science ®Google Scholar
• Shang S, Zhou D, Ya J, et al. Progress in moyamoya disease. Neurosurg Rev. 2020;43(2):371–382. doi: 10.1007/s10143-018-0994-5.
   PubMed Web of Science ®Google Scholar
• Nagel MA, Niemeyer CS, Bubak AN. Central nervous system infections produced by varicella zoster virus. Curr Opin Infect Dis. 2020;33:272–278.
   Web of Science ®Google Scholar
• Maramattom BV. Postcryptococcal moyamoya syndrome: case report and review of literature. Neurol India. 2020;68(3):660–664.
   PubMed Web of Science ®Google Scholar
• Aoyagi M, Fukai N, Sakamoto H, et al. Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol. 1991;147(2):191–198.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Houkin K, Takahashi A, et al. Angiogenic factors in moyamoya disease. Stroke. 1996;27:2160–2165.
   PubMed Web of Science ®Google Scholar
• Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106:470–476.
   PubMed Web of Science ®Google Scholar
• Tekesin A, Tunç AA-O. Inflammatory markers are beneficial in the early stages of cerebral venous thrombosis. Arq Neuropsiquiatr. 2019;77(2):101–105.
   PubMed Web of Science ®Google Scholar
• Hoshimaru M, Takahashi JA, Kikuchi H, et al. Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: an immunohistochemical study. J Neurosurg. 1991;75:267–270.
   PubMed Web of Science ®Google Scholar
• Schaider H, Oka M, Bogenrieder T, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer. 2003;103(3):335–343.
   PubMed Web of Science ®Google Scholar
• Kang H-S, Kim JH, Phi JH, et al. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. J Neurol Neurosurg Psychiatry. 2010;81(6):673–678. doi:10.1136/jnnp.2009.191817.
   PubMed Web of Science ®Google Scholar
• Shamamian P, Schwartz JD, Pocock BJ, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol. 2001;189(2):197–206.
   Google Scholar
• Aldabbous L, Abdul-Salam V, McKinnon T, et al. Neutrophil extracellular traps promote angiogenesis: evidence from vascular pathology in pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2016;36(10):2078–2087. doi:10.1161/ATVBAHA.116.307634.
   PubMed Web of Science ®Google Scholar
• Kyaw TA-O, Peter K, Li Y, et al. Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges. Br J Pharmacol. 2017;174(22):3956–3972.
   PubMed Web of Science ®Google Scholar
• Mulholland M, Jakobsson G, Lei Y, et al. IL-2Rβγ signalling in lymphocytes promotes systemic inflammation and reduces plasma cholesterol in atherosclerotic mice. Atherosclerosis. 2021;326:1–10.
   PubMed Web of Science ®Google Scholar
• Weinberg DG, Arnaout OM, Rahme RJ, et al. Moyamoya disease: a review of histopathology, biochemistry, and genetics. Neurosurg Focus. 2011;30(6):E20.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Oka K, Tanaka K. Cervico-cephalic arterial thrombi and thromboemboli in moyamoya disease – possible correlation with progressive intimal thickening in the intracranial major arteries. Stroke. 1984;15(2):264–270. doi:10.1161/01.str.15.2.264.
   PubMed Web of Science ®Google Scholar
• MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension—from bench to bedside? Curr Opin Pharmacol. 2009;9:281–286.
   PubMed Web of Science ®Google Scholar
• Hood KY, Mair KM, Harvey AP, et al. Serotonin signaling through the 5-HT1B receptor and NADPH oxidase 1 in pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2017;37(7):1361–1370.
   PubMed Web of Science ®Google Scholar
• Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99(3):249–254.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li J, Lu J, et al. Predictors of neoangiogenesis after indirect revascularization in moyamoya disease: a multicenter retrospective study. J Neurosurg. 2019;1–11. doi:10.3171/2018.9.JNS181562.
   Google Scholar